IL6 and chronic kidney disease: This trial assessed the effects of ziltivekimab, a fully human monoclonal antibody directed against the IL-6 ligand with extended half-life technology, on multiple biomarkers of inflammation and thrombosis in patients at high cardiovascular risk with moderate to severe chronic kidney disease (CKD) and elevated hsCRP.